Achievements
-
.Newmedicine
for children, Pyramax® granules (pyronaridine-artesunate), co-developed with Shin Poong, added to the WHO list of prequalified medicines
-
.8potential new medicines
in clinical development prioritizing treatment for vulnerable populations and supporting malaria eradication
-
.USD 1= USD 3.5
of investment impact thanks to direct and in-kind support from partners
Defeating malaria together
Featured resources
-
2,3,8-Trisubstituted Quinolines with Antimalarial Activity
May 2018 -
Rapport de gestion 2017
MMV's Management Report in French
Jun 2018 -
Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
Jun 2018
Events
-
15Jul
22nd North American ISSX Meeting
15 - 19 July 2018Montreal, Canada -
10Sep
Training course: Clinical research operations for study coordinators
The course runs for 12 weeks starting 10 September 2018Online -
28Oct
ASTMH 67th Annual Meeting
28 October - 1 November 2018New Orleans, Louisiana USA